MX2016002794A - Compuestos antiproliferativos. - Google Patents

Compuestos antiproliferativos.

Info

Publication number
MX2016002794A
MX2016002794A MX2016002794A MX2016002794A MX2016002794A MX 2016002794 A MX2016002794 A MX 2016002794A MX 2016002794 A MX2016002794 A MX 2016002794A MX 2016002794 A MX2016002794 A MX 2016002794A MX 2016002794 A MX2016002794 A MX 2016002794A
Authority
MX
Mexico
Prior art keywords
compounds
compositions
antiproliferative compounds
present
kdm5
Prior art date
Application number
MX2016002794A
Other languages
English (en)
Inventor
Yves Leblanc
Jun Liang
Birong Zhang
K Albrecht Brian
F Bellon Steven
S Gehling Victor
Christophe Harmange Jean-
R Magnuson Steve
Hsiao- Wei Tsui Vickie
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2016002794A publication Critical patent/MX2016002794A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere a compuestos de la fórmula (I) y a sales de estos, donde R1-R4 y A tienen cualquiera de los valores definidos en la memoria descriptiva, y composiciones y usos de estos. Los compuestos son útiles como inhibidores de histona desmetilasas, tales como KDM5. También se incluyen composiciones farmacéuticamente aceptables que comprenden los compuestos de la presente invención y métodos para usar dichas composiciones en el tratamiento de diversos trastornos.
MX2016002794A 2013-09-05 2014-09-04 Compuestos antiproliferativos. MX2016002794A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361874310P 2013-09-05 2013-09-05
PCT/US2014/054114 WO2015035062A1 (en) 2013-09-05 2014-09-04 Antiproliferative compounds

Publications (1)

Publication Number Publication Date
MX2016002794A true MX2016002794A (es) 2016-09-13

Family

ID=51541384

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002794A MX2016002794A (es) 2013-09-05 2014-09-04 Compuestos antiproliferativos.

Country Status (10)

Country Link
US (1) US9505767B2 (es)
EP (1) EP3041474B1 (es)
JP (1) JP6336598B2 (es)
KR (1) KR20160049003A (es)
CN (1) CN105611933B (es)
CA (1) CA2922925A1 (es)
HK (1) HK1221421A1 (es)
MX (1) MX2016002794A (es)
RU (1) RU2016112568A (es)
WO (1) WO2015035062A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015007083A2 (pt) 2012-10-02 2017-07-04 Epitherapeutics Aps inibidores de histona demetilases
AP2015008676A0 (en) 2013-02-27 2015-08-31 Epitherapeutics Aps Inhibitors of histone demethylases
US10035801B2 (en) 2013-03-13 2018-07-31 Genentech, Inc. Pyrazolo compounds and uses thereof
SG11201701182VA (en) 2014-08-27 2017-03-30 Gilead Sciences Inc Compounds and methods for inhibiting histone demethylases
MX2017005346A (es) 2014-10-29 2017-08-02 Dong A St Co Ltd Nuevos compuestos de piridopirimidinona para modular la actividad catalitica de histona lisina desmetilasas (kdm).
WO2016186949A1 (en) * 2015-05-15 2016-11-24 Whetstine Johnathan R Methods relating to the prevention and treatment of drug resistance
EP3507290A1 (en) 2016-08-31 2019-07-10 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
US20200048259A1 (en) * 2016-10-12 2020-02-13 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2018160356A1 (en) 2017-02-28 2018-09-07 University Of Massachusetts Genetic and pharmacological transcriptional upregulation of the repressed fxn gene as a therapeutic strategy for friedreich ataxia
CN108947985A (zh) * 2017-05-22 2018-12-07 苏州偶领生物医药有限公司 用作自噬调节剂的化合物及其制备方法和用途
CN111886225A (zh) * 2017-08-21 2020-11-03 纳维根公司 Arf6抑制剂及相关方法
KR20200032751A (ko) * 2017-09-15 2020-03-26 아두로 바이오테크, 인코포레이티드 피라졸로피리미디논 화합물 및 그의 용도
CA3144401A1 (en) * 2019-06-24 2020-12-30 Dana-Farber Cancer Institute, Inc. E3 ligase binders and uses thereof
US20220289751A1 (en) * 2019-07-17 2022-09-15 Ono Pharmaceutical Co., Ltd. Compound having kdm5 inhibitory activity and pharmaceutical use thereof
AU2020392087A1 (en) 2019-11-25 2022-06-09 Amgen Inc. Heterocyclic compounds as Delta-5 Desaturase inhibitors and methods of use
CN116425757A (zh) * 2022-01-13 2023-07-14 浙江同源康医药股份有限公司 多环类化合物及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
WO1991003489A1 (en) 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
PT659439E (pt) 1993-12-24 2002-04-29 Merck Patent Gmbh Imunoconjugados
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE69507956T2 (de) 1994-07-21 1999-09-09 Akzo Nobel Nv Zyklische keton peroxyde zubereitungen
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
CA2224435C (en) 1995-07-06 2008-08-05 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
ATE227283T1 (de) 1996-07-13 2002-11-15 Glaxo Group Ltd Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
PT980244E (pt) 1997-05-06 2003-10-31 Wyeth Corp Utilizacao de compostos de quinazolina para o tratamento da doenca policistica renal
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AU1308799A (en) 1997-11-06 1999-05-31 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
WO2000031048A1 (en) 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
JP4100865B2 (ja) * 1999-12-13 2008-06-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 三環式縮合異項環化合物、その製造法およびその医薬
EP1511751B1 (en) 2002-06-04 2008-03-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidine compounds as antiviral agents
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
JP5284955B2 (ja) * 2006-06-20 2013-09-11 アボット・ラボラトリーズ Ｐａｒｐ阻害剤としてのピラゾロキナゾリノン
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
CN101906105B (zh) * 2009-06-08 2013-01-16 河北医科大学 吡唑并[1，5-a]嘧啶酮衍生物及其药物组合物以及其用途
WO2012149157A2 (en) * 2011-04-26 2012-11-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2014066795A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2014131855A1 (en) * 2013-03-01 2014-09-04 Fundación Para La Investigación Médica Aplicada Novel compounds as dual inhibitors of phosphodiesterases and histone deacetylases
US10035801B2 (en) 2013-03-13 2018-07-31 Genentech, Inc. Pyrazolo compounds and uses thereof

Also Published As

Publication number Publication date
US9505767B2 (en) 2016-11-29
CA2922925A1 (en) 2015-03-12
HK1221421A1 (zh) 2017-06-02
CN105611933A (zh) 2016-05-25
CN105611933B (zh) 2019-01-25
EP3041474B1 (en) 2020-03-18
JP2016529312A (ja) 2016-09-23
KR20160049003A (ko) 2016-05-04
US20150065522A1 (en) 2015-03-05
RU2016112568A3 (es) 2018-08-08
RU2016112568A (ru) 2017-10-06
JP6336598B2 (ja) 2018-06-06
EP3041474A1 (en) 2016-07-13
WO2015035062A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
MX2016002794A (es) Compuestos antiproliferativos.
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
AU2019268062A1 (en) Benzoquinolone inhibitors of VMAT2
IN2015DN01156A (es)
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
MX2017004200A (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
PH12018500061A1 (en) Oxysterols and methods of use thereof
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MX2015012850A (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
MX364486B (es) Derivados de piridazinona-amidas.
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
EA201500931A1 (ru) Производные пиридин-4-ила
GEP20186876B (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases